Fibromyalgia affects an estimated 2 to 4% of the global population, causing widespread chronic pain, fatigue, cognitive difficulties, and a collection of other symptoms that have frustrated patients and physicians for decades. The condition has no identifiable tissue damage, no reliable biomarker, and no treatment that works consistently. Many patients report being told their pain is psychosomatic or that nothing is physically wrong with them. A 2025 study published in Neuron may begin to change that narrative. Researchers at McGill University took gut bacteria from fibromyalgia patients, transplanted them into mice with no prior microbiome, and watched those mice develop widespread pain hypersensitivity within days. No inflammation. No nerve damage. No tissue injury of any kind. Just pain, induced by bacteria from the gut of someone who lives with this condition. When the researchers then gave those same mice gut bacteria from healthy donors, the pain went away. The implications of this finding, if it translates to humans, are substantial. It suggests that fibromyalgia may be, at least in part, a disorder of the gut microbiome rather than a disorder of the brain or peripheral nerves. But that translation is not guaranteed, and the gap between an elegant mouse study and an effective human treatment is historically large in pain research.
What the 2025 study actually did
The study, led by Amir Bhatt and colleagues in the laboratory of Yoram Bhatt at McGill University's Alan Edwards Centre for Research on Pain, used a well-established experimental approach called fecal microbiota transplantation (FMT) into germ-free mice. Germ-free mice are raised in completely sterile environments and have no gut bacteria of their own, making them a blank slate for microbiome experiments. The researchers collected stool samples from fibromyalgia patients who met standard diagnostic criteria and from age-matched and sex-matched healthy controls with no chronic pain conditions (Bhatt et al., 2025).
They transplanted these stool samples into separate groups of germ-free mice and then tested the mice for pain sensitivity over the following weeks. The primary outcome measures included mechanical sensitivity (tested by applying calibrated filaments to the paws), thermal sensitivity (tested by measuring response latency to heat), and cold sensitivity (tested by measuring responses to cold surfaces). These are standard behavioral pain tests used across preclinical research.
The results were clear. Mice that received FMT from fibromyalgia patients developed significantly increased sensitivity across all three pain modalities within 5 to 7 days of transplantation. They flinched at lighter touches, withdrew from heat faster, and reacted more strongly to cold compared to mice that received FMT from healthy controls. Importantly, this pain hypersensitivity occurred without any signs of tissue inflammation, nerve damage, or peripheral injury. Histological examination of the mice's paws, nerves, and spinal cords showed no pathological changes. The pain appeared to be genuinely nociplastic, arising from altered pain processing rather than from damage to the tissues.
The reversal: healthy FMT normalized pain
The most striking aspect of the study was the reversal experiment. After establishing pain hypersensitivity with fibromyalgia-patient FMT, the researchers performed a second FMT using stool from healthy donors. Within a comparable timeframe, the mice's pain sensitivity returned to normal levels. This bidirectional effect is important for several reasons.
First, it demonstrates that the pain state is actively maintained by the microbial community rather than resulting from a permanent change triggered by the initial exposure. If the fibromyalgia microbiome had caused lasting nerve damage or permanent sensitization, healthy FMT would not have reversed it. The fact that it did suggests ongoing microbial signaling is required to sustain the pain phenotype.
Second, the reversal provides a stronger argument for causation than the initial induction alone. Many substances can induce pain when introduced into an organism; fewer can both induce and resolve it through the same type of intervention with different donors. This reciprocal pattern makes confounding explanations less likely, though the germ-free mouse model introduces its own confounds that must be acknowledged.
⚠️Germ-free mice have abnormally developed immune systems, altered gut barrier function, and differences in nervous system development compared to conventionally raised mice. These baseline abnormalities mean that their responses to microbial colonization may not perfectly mirror what would happen in a human with an established microbiome. The study is mechanistically compelling, but the germ-free model is an imperfect proxy for human biology.
How gut bacteria might produce pain without tissue damage
The concept that bacteria in the gut can influence pain perception in distant parts of the body is not as far-fetched as it might initially seem. Multiple established pathways connect the gut microbiome to the nervous system, and several of these pathways are directly relevant to pain processing.
Proposed mechanisms linking gut bacteria to pain
- Neuroactive metabolites: Gut bacteria produce compounds that directly affect nervous system function, including gamma-aminobutyric acid (GABA), serotonin precursors, and short-chain fatty acids. Altered production of these metabolites could shift the excitability of pain-processing neurons in the spinal cord and brain.
- Vagus nerve signaling: The vagus nerve provides a direct neural connection between the gut and the brain. Bacterial products can activate vagal afferents, sending signals that modulate pain processing in the central nervous system.
- Systemic cytokine release: Gut dysbiosis can increase intestinal permeability and promote low-grade systemic inflammation. Circulating pro-inflammatory cytokines can sensitize peripheral and central pain pathways, lowering the threshold for pain perception.
- Bile acid alterations: The 2019 Minerbi study found altered bile acid profiles in fibromyalgia patients. Bile acids are modified by gut bacteria and can activate receptors on sensory neurons, potentially altering pain sensitivity.
- Glutamate metabolism: Fibromyalgia patients showed altered levels of glutamate, the primary excitatory neurotransmitter in the nervous system. Gut bacteria influence systemic glutamate levels through amino acid metabolism, and elevated glutamate in the central nervous system is associated with central sensitization.
The 2019 precursor study by Minerbi et al. had already identified 19 bacterial species whose abundance was significantly altered in fibromyalgia patients compared to controls. These species accounted for enough variance in the data that a machine learning algorithm could diagnose fibromyalgia based on gut microbiome composition alone with reasonable accuracy. Several of the altered species are known producers or modulators of neuroactive compounds, providing a mechanistic bridge between the microbiome data and the pain phenotype observed in the 2025 FMT study.
What this means for people with fibromyalgia
For the millions of people living with fibromyalgia, this research offers something that has been in short supply: a biologically grounded explanation for their pain that does not rely on psychological framing or diagnostic exclusion. The study demonstrates that the gut microbiome can produce a pain state that looks very much like fibromyalgia in an animal model, and that this pain state is reversible. That is meaningful, even if it is not yet actionable at the clinical level.
However, it is important to be clear about what this study does not show. It does not show that FMT will work as a treatment for fibromyalgia in humans. Human FMT trials for fibromyalgia have not been completed. It does not show that any specific probiotic, prebiotic, or dietary intervention will reduce fibromyalgia pain. It does not identify a cure or even a specific therapeutic target. What it does is change the scientific conversation about where fibromyalgia pain comes from, and that change in understanding could eventually lead to new treatment approaches.
What helps right now: practical considerations
While waiting for clinical trials to translate this mouse data into human treatments, people with fibromyalgia can consider several gut-focused approaches that are generally safe and supported by broader microbiome research, even if they have not been specifically validated for fibromyalgia pain reduction.
- Dietary fiber diversity: Eating a wide range of plant-based fibers supports microbial diversity and short-chain fatty acid production, both of which are associated with reduced systemic inflammation and better nervous system function.
- Identifying food-symptom patterns: Many fibromyalgia patients report that certain foods worsen their pain. Systematically tracking food intake and pain levels with a tool like GLP1Gut can help identify individual triggers that might be worth discussing with your healthcare provider.
- Addressing concurrent IBS: Between 32% and 70% of fibromyalgia patients also meet criteria for irritable bowel syndrome (Whitehead et al., 2002). Treating IBS symptoms may not resolve fibromyalgia, but reducing gut-related distress can improve overall quality of life and may reduce the microbial signals contributing to pain.
- Discussing gut health with your doctor: If your fibromyalgia management has not included any consideration of gut health, this research provides a reasonable basis for that conversation. Ask about testing for SIBO, celiac disease, or other gut conditions that could be contributing to your symptom burden.
- Exercising caution with commercial FMT or microbiome products: Some online sources promote FMT or aggressive microbiome interventions for fibromyalgia. These are not validated treatments and carry real risks, particularly outside regulated medical settings.
What comes next in the research
The logical next step is a human clinical trial testing FMT in fibromyalgia patients. As of early 2026, at least two research groups have announced plans for such trials, though none have reported results. These trials will need to address several questions beyond whether FMT reduces pain: what constitutes an ideal donor, how many treatments are needed, how long effects persist, and whether the host's original microbiome reasserts itself over time.
Another research direction involves identifying the specific bacterial species or metabolites responsible for the pain phenotype and developing targeted interventions rather than wholesale microbiome replacement. If a small number of species drive the effect, it might be possible to develop a defined bacterial consortium or even a postbiotic (bacterial metabolite) therapy that avoids the complexity and variability of FMT.
The broader significance of this research extends beyond fibromyalgia. If gut bacteria can induce widespread pain without tissue damage in one condition, the same mechanisms could be relevant to other chronic pain conditions that lack clear peripheral pathology, including chronic fatigue syndrome, chronic pelvic pain, and some forms of chronic low back pain. The gut-pain axis may turn out to be as significant as the gut-brain axis in understanding how the microbiome affects human health.
**Disclaimer:** This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider about your specific health concerns.
Does this study prove that fibromyalgia is caused by gut bacteria?
It provides strong evidence that gut bacteria can produce fibromyalgia-like pain in mice, but it does not prove that human fibromyalgia is caused by gut bacteria. The study used germ-free mice, which have abnormal baseline physiology, and the translation from mouse pain models to human pain conditions has historically been unreliable. The study strongly supports the hypothesis that the gut microbiome plays a causal role in fibromyalgia pain, but confirmation requires human interventional trials that have not yet been completed.
Should fibromyalgia patients try FMT based on this research?
No. FMT is not a validated treatment for fibromyalgia, and no human trial has tested it for this purpose. FMT outside of regulated medical settings carries risks including transmission of antibiotic-resistant organisms and other infections. The mouse study is an important scientific advance, but attempting to replicate it outside a clinical trial setting is not advisable.
Can probiotics help with fibromyalgia pain?
There is very limited evidence for probiotics specifically reducing fibromyalgia pain. A small number of pilot studies have reported modest improvements in symptoms with certain probiotic strains, but these studies are too small and too heterogeneous to draw conclusions. The 2025 FMT study suggests that wholesale microbiome replacement might be more effective than individual probiotic strains, since the pain phenotype appears to involve complex community-level effects rather than the absence of a single species.
Why do so many fibromyalgia patients also have IBS?
The overlap between fibromyalgia and IBS ranges from 32% to 70% depending on the study and diagnostic criteria used. Both conditions involve altered pain processing without identifiable tissue damage, and both are now associated with gut microbiome alterations. The 2025 study suggests a possible explanation: if gut bacteria can modulate pain sensitivity systemically, the same dysbiotic community could produce both visceral pain (experienced as IBS) and widespread body pain (experienced as fibromyalgia). Shared mechanisms in the gut-brain axis, including vagal signaling and central sensitization, likely contribute to the high comorbidity.